An Intervention Trial for Cardiac Neuropathy in Type 1 Diabetes

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The focus of this project is cardiovascular diabetic autonomic neuropathy (DAN). DAN affects the nerves that control heart rate and blood flow to the heart in people with diabetes. DAN may cause problems with the rhythm of the heartbeat or decrease blood flow to the heart. Three medications will be tested for their effectiveness in DAN.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Michigan
• Collaborator: Juvenile Diabetes Research Foundation
• Treatments: Allopurinol; Antioxidants; Niacin; Niacinamide; Nicotinic Acids

Criteria

Inclusion Criteria:

• Type 1 diabetes

• A1C <9%

• Mild neuropathy

• Mild retinopathy

• Mild nephropathy

Exclusion Criteria:

• History of drug or alcohol dependence, heart disease, viral illness, liver disease, advanced kidney disease

• Pregnant or nursing

• Severely overweight